IRT and CMT β-lactamases and inhibitor resistance

被引：85

作者：

Canton, R. ^{[1
]}

Morosini, M. I. ^{[1
]}

Martin, O. ^{[1
]}

de la Maza, S. ^{[1
]}

de la Pedrosa, E. Gomez G. ^{[1
]}

机构：

[1] Hosp Univ Ramon & Cajal, Microbiol Serv, Madrid 28034, Spain

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2008年 / 14卷

关键词：

class A beta-lactamase inhibitors; clavulanate; inhibitor-resistant beta-lactamases; IRT; review;

D O I：

10.1111/j.1469-0691.2007.01849.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Acquired resistance to penicillin-beta-lactamase inhibitor combinations in Escherichia coli is due to: (i) penicillinase hyperproduction due to the presence of the bla(TEM-1) gene in small multicopy plasmids or strong promoters; (ii) overproduction of constitutive AmpC cephalosporinase; and (iii) OXA-type and inhibitor-resistant TEM (IRT) beta-lactamases. IRT enzymes emerge via mutational events from TEM-1 or TEM-2 beta-lactamases that affect substrate affinity for v-lactamase inhibitors. They are mainly isolated in urinary infections from community patients. Prevalence is variable, depending on geographical area, detection methods and potential selection pressure. These enzymes may evolve into complex mutants (CMT enzymes), which also confer resistance to extended-spectrum cephalosporins. CTX-M enzymes with the IRT phenotype have not been detected to date. New studies of IRT enzymes, including population structure, association with virulence traits and plasmid dispersion, are needed.

引用

页码：53 / 62

页数：10

共 67 条

[1] TEM-80, a novel inhibitor-resistant β-lactamase in a clinical isolate of Enterobacter cloacae [J].

Arpin, C ;

Labia, R ;

Dubois, W ;

Noury, P ;

Souquet, M ;

Quentin, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1183-1189

[2] Selective compartments for resistant microorganisms in antibiotic gradients [J].

Baquero, F ;

Negri, MC .

BIOESSAYS, 1997, 19 (08) :731-736

[3] CHARACTERIZATION OF A NEW TEM-TYPE BETA-LACTAMASE RESISTANT TO CLAVULANATE, SULBACTAM, AND TAZOBACTAM IN A CLINICAL ISOLATE OF ESCHERICHIA-COLI [J].

BLAZQUEZ, J ;

BAQUERO, MR ;

CANTON, R ;

ALOS, I ;

BAQUERO, F .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) :2059-2063

[4]

Bonomo R.A., 1999, FRONT BIOSCI, V4, P34

[5] Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases [J].

Bonomo, RA ;

Rudin, SA ;

Shlaes, DM .

FEMS MICROBIOLOGY LETTERS, 1997, 148 (01) :59-62

[6] Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada [J].

Boyd, DA ;

Tyler, S ;

Christianson, S ;

McGeer, A ;

Muller, MP ;

Willey, BM ;

Bryce, E ;

Gardam, M ;

Nordmann, P ;

Mulvey, MR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :3758-3764

[7] Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City [J].

Bradford, PA ;

Bratu, S ;

Urban, C ;

Visalli, M ;

Mariano, N ;

Landman, D ;

Rahal, JJ ;

Brooks, S ;

Cebular, S ;

Quale, J .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (01) :55-60

[8]

BUSH K, 1988, Clinical Microbiology Reviews, V1, P109

[9] Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinations [J].

Buynak, JD .

BIOCHEMICAL PHARMACOLOGY, 2006, 71 (07) :930-940

[10] Molecular diversity and evolution of bla(TEM) genes encoding beta-lactamases resistant to clavulanic acid in clinical E-coli [J].

Canica, MMM ;

Lu, CY ;

Krishnamoorthy, R ;

Paul, GC .

JOURNAL OF MOLECULAR EVOLUTION, 1997, 44 (01) :57-65

← 1 2 3 4 5 6 7 →